RheumaGen, Inc.

Plus, news about RheumaGen and RyboDyn: Numab Therapeutics brings in $55M: The Swiss biotech extended its Series C, originally disclosed in 2021 , by CHF 50 million. The round now totals CHF 180 million ($197 million). Last year, Johnson & Johnson bought a Numab spinout called Yellow Jersey Therapeutics. The startup has inked multiple partnerships over the years with Kaken, Ono and others. — Kyle LaHucik AnaCardio raises $19M for heart failure pill: The Swedish biotech extended its Series A round , bringing the total raised to SEK 355 million ($32 million). It said it will put the cash from investors like Novo Holdings toward an ongoing Phase 1b/2a trial of its oral ghrelin receptor agonist in heart failure with reduced ejection fraction. AC01 was licensed from Helsinn in 2022, and a Phase 2b study is planned. — Elizabeth Cairns Colorado gene editing startup gets $15M: RheumaGen’s focus is editing the human leukocyte antigen to develop cell and gene therapies for autoimmune diseases. It plans to use its Series A toward an early-stage study of a treatment for rheumatoid arthritis. The financing was led by SPRIM Global Investments and William Taylor Nominees. — Lei Lei Wu RyboDyn gets $4M to investigate the “dark proteome”: The biotech’s pre-seed round is expected to fund development of cancer immunotherapies using RyboCypher, its sequencing and bioinformatics platform, to work on non-coding DNA. Some of these regions can, in fact, encode proteins that are exclusively expressed in cancer cells, the company said. — Elizabeth Cairns